Dr. Reddy's Laboratories Limited (RDY) Revenue History
Annual and quarterly revenue from 2001 to present
RDY Revenue Over Time (2001–2026)
RDY Revenue Growth History
21 of 25 years with positive growth- FY2001 revenue growth
- N/A
- FY2002 revenue growth
- +51.8%
- FY2003 revenue growth
- +8.5%
- FY2004 revenue growth
- +11.7%
- FY2005 revenue growth
- -3.2%
- FY2006 revenue growth
- +24.9%
- FY2007 revenue growth
- +168.2%
- FY2008 revenue growth
- -23.4%
- FY2009 revenue growth
- +38.9%
- FY2010 revenue growth
- +1.2%
- FY2011 revenue growth
- +6.3%
- FY2012 revenue growth
- +29.5%
- FY2013 revenue growth
- +20.2%
- FY2014 revenue growth
- +13.7%
- FY2015 revenue growth
- +12.1%
- FY2016 revenue growth
- +4.4%
- FY2017 revenue growth
- -9.0%
- FY2018 revenue growth
- +0.9%
- FY2019 revenue growth
- +8.3%
- FY2020 revenue growth
- +13.5%
- FY2021 revenue growth
- -98.5%
- FY2022 revenue growth
- +8288.8%
- FY2023 revenue growth
- +14.7%
- FY2024 revenue growth
- +13.5%
- FY2025 revenue growth
- +16.6%
- FY2026 revenue growth
- +8.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2026 | $76.33B | -10.3% |
| Q3 2026 | $87.27B | +4.4% |
| Q2 2026 | $88.05B | +9.8% |
| Q1 2026 | $85.45B | +11.4% |
| Q4 2025 | $85.06B | +20.1% |
| Q3 2025 | $83.59B | +15.9% |
| Q2 2025 | $80.16B | +9532.6% |
| Q1 2025 | $76.73B | +13.9% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown
RDY's revenue distribution by segment and geography
By Geography
RDY Revenue Analysis (2001–2026)
Current Revenue & Growth
As of June 29, 2026, Dr. Reddy's Laboratories Limited (RDY) generated trailing twelve-month (TTM) revenue of $337.10 billion, reflecting significant decline in growth of -10.3% year-over-year. The most recent quarter (Q4 2026) recorded $76.33 billion in revenue, down 12.5% sequentially.
Historical Growth Trajectory
RDY's 5-year compound annual growth rate (CAGR) stands at +168.0%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +12.9% is below the 5-year average, signalling a growth deceleration in recent years. Dr. Reddy's Laboratories Limited's highest annual revenue of $353.47 billion was recorded in 2026, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including SUN (+37.3% YoY), PRGO (-3.6% YoY), and AMRX (+7.6% YoY) — RDY has underperformed the peer group in revenue growth. Compare RDY vs SUN →
RDY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RDYCurrent | $337.1B | -10.3% | +168.0% | 13.8% | |
 SUN | $25.2B | +37.3% | +18.7% | 3.7% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 AMRX | $3.0B | +7.6% | +8.7% | 14.0% | |
 TEVA | $17.3B | +4.4% | +0.7% | 12.5% | |
 VTRS | $14.3B | +1.6% | +3.7% | -18.6% |
RDY Historical Revenue Data (2001–2026)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | $353.47B | +8.6% | $186.52B | 52.8% | $48.87B | 13.8% |
| 2025 | $325.54B | +16.6% | $190.43B | 58.5% | $71.84B | 22.1% |
| 2024 | $279.16B | +13.5% | $163.61B | 58.6% | $67.73B | 24.3% |
| 2023 | $245.88B | +14.7% | $139.34B | 56.7% | $57.14B | 23.2% |
| 2022 | $214.39B | +8288.8% | $113.84B | 53.1% | $29.48B | 13.7% |
| 2021 | $2.56B | -98.5% | $1.30B | 50.8% | $431.4M | 16.9% |
| 2020 | $174.60B | +13.5% | $94.01B | 53.8% | $15.99B | 9.2% |
| 2019 | $153.85B | +8.3% | $83.43B | 54.2% | $20.89B | 13.6% |
| 2018 | $142.03B | +0.9% | $76.30B | 53.7% | $11.92B | 8.4% |
| 2017 | $140.81B | -9.0% | $78.36B | 55.6% | $13.50B | 9.6% |
| 2016 | $154.71B | +4.4% | $92.28B | 59.6% | $29.62B | 19.1% |
| 2015 | $148.19B | +12.1% | $85.40B | 57.6% | $26.29B | 17.7% |
| 2014 | $132.17B | +13.7% | $75.80B | 57.4% | $26.03B | 19.7% |
| 2013 | $116.27B | +20.2% | $60.58B | 52.1% | $21.11B | 18.2% |
| 2012 | $96.74B | +29.5% | $53.30B | 55.1% | $18.25B | 18.9% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RDY — Frequently Asked Questions
Quick answers to the most common questions about buying RDY stock.
Is RDY's revenue growth accelerating or slowing?
RDY revenue is declining -10.3% year-over-year. TTM revenue fell to $337.1B, contrasting with the 5-year CAGR of +168.0%. The reversal reflects either macro headwinds or company-specific challenges.
What is RDY's revenue history from 2001 to 2026?
Dr. Reddy's Laboratories Limited (RDY) revenue history spans 2001 to 2026. TTM revenue as of 2026 is $337.1B, growing at -10.3% YoY. The 5-year CAGR is +168.0%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is RDY's long-term revenue growth rate (CAGR)?
Dr. Reddy's Laboratories Limited's 5-year revenue CAGR of +168.0% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -10.3% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for RDY.
Why does RDY's quarterly revenue fluctuate?
RDY quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Dr. Reddy's Laboratories Limited's revenue data from 2001 to 2026 shows full historical quarterly detail on this page.
How is RDY's revenue distributed by segment?
RDY reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does RDY's revenue compare to industry peers?
Dr. Reddy's Laboratories Limited (RDY) with TTM revenue of $337.1B and -10.3% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.